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A commentary on
Successful therapies for Alzheimer’s dis-
ease: why so many in animal models and
none in humans?
by Franco R, Cedazo-Minguez A. Front
Pharmacol (2014) 5:146. doi:10.3389/ fphar.
2014.00146
Franco and Cedazo-Minguez, in their
review, raised the issue that animal mod-
els have a poor predictability with respect
to drug development in the field of
Alzheimer’s disease (AD) (1). Although this
critical paper touches upon highly relevant
issues in the development of new drugs,
various other factors can be suggested,
which also complicate the translation from
animal studies to human studies. Here, we
briefly discuss these issues relating to the
development of cognition enhancers.
MODEL AND TEST VALIDITY: DO YOU
MEASURE THE SAME?
A first issue is that the models that are
being used in animal experiments have a
poor validity. This relates to the deficit
model that reflects a disease model, or the
test model in which the behavior is inter-
preted in terms of learning and memory
(2). There are various disease models for
impaired learning and memory: pharma-
cological deficit models, lesion models, and
genetic models [for review, see Ref. (3)].
Since these models can only mimic a spe-
cific aspect of a complex disease state, it is
not surprising that these models can only
have a limited value when new compounds
are tested in these models. In addition, the
use of test models puts another constraint
on the translation of effects of drug. In
human studies, episodic memory tests (in
particular, verbal memory) or daily activi-
ties (ADL scales) are of special interest in
assessing effects of drug on cognition. The
face validity of animal test models (e.g.,
spatial Morris task,object memory) is obvi-
ously rather poor when comparing these
memory capacities. In summary, it is clear
that both disease models and test mod-
els have limited validity when translating
effects of drug from animals to humans.
PHARMACOLOGY: DOSING AND
PHARMACOKINETICS?
A second formidable challenge is to pre-
dict the efficacious dose of CNS drugs from
animals to human (4). Several aspects are
related to this point. CNS drugs typically
show an inverted U-shaped dose–response
curve, meaning that only a specific dose
range leads to a beneficial effect on cog-
nition. Especially, when the effective dose
range is very narrow in animal studies,
it will be difficult to titrate an effective
dose for human studies. Moreover, side
effects can be found at different doses
across species with the consequence that
the therapeutic window of drugs can be
different for animals and humans. Another
issue that could be mentioned in this con-
text is related to the acute and chronic
effects of drugs. Most animal studies evalu-
ate the acute effects of cognition-enhancing
drugs, whereas in human disease states,
chronic treatments are considered to be
more relevant. Eventually, chronic drug
treatment is usually required for treating
patients. However, chronic effects of drug
may differ from acute effects of drugs.
For instance, in healthy volunteers, a phos-
phodiesterase type 5 (PDE5) inhibitor was
not effective on cognitive measures after
acute treatment (5), although an effect
on memory performance was found after
chronic treatment with a PDE5 inhibitor
(6). An additional point to be mentioned
in this context is that the pharmacodynam-
ics/pharmacokinetics for most drugs is dif-
ferent between species. For instance, PDE
inhibitors have a short half-life in animals
(7, 8), whereas in humans the half-life of
PDE inhibitors is in general extended (9).
In addition, the absorption and brain pen-
etration are much faster in small experi-
mental animals when compared to humans
(10). Recently, we conducted a study in
which we found significant brain penetra-
tion of PDE inhibitors within 10 minutes in
rats after oral administration (unpublished
data). This is much faster as can be expected
in humans when considering species differ-
ences in plasma concentrations after drug
administration. It is well known that psy-
chopharmacological effects of drugs can be
very different if the rate of absorption and
brain penetration is fast or slow (11). Sum-
marizing, there are many pharmacological
factors for which animals and humans dif-
fer, which may explain differences in the
effects on brain function. These are impor-
tant points to consider when testing the
effects of cognition-enhancing drugs in
humans.
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HOUSING: IS YOUR ENVIRONMENT THE
SAME?
A third and final general point we would
like to raise in this commentary is related
to the animals that are being used in most
experimental studies. It has been suggested
that standard housed animals may not be
valid test models for the evaluation of cog-
nition enhancing drugs (12). It was stated
that due to a different brain development,
standard housed animals could be con-
sidered as having an impoverished brain,
and that this did not compare to nor-
mal brain development in humans [see
also Ref. (13)]. Indeed, there are many
differences between standard housed ani-
mals and animals raised in an enriched
environment. Enriched animals outper-
form standard housed animals in many
cognitive tasks, and the brain chemistry
shows remarkable differences (14). Thus,
enriched animals may resemble normal
human brain development much better as
compared to standard housed animals.
We recently conducted a study in which
we tested the effects of a PDE5 inhibitor
in enriched and standard housed animals
(paper under review). Although we repli-
cated our previous findings that acute
treatment with PDE5 inhibitors improves
memory performance in standard housed
animals, we could not find a cognition
enhancing effect of PDE5 inhibition in
enriched animals. The lack of effect in
enriched animals corroborate the human
study with acute PDE5 treatment and sug-
gest that standard housed animals may not
be considered as relevant test models for
cognition enhancing drugs.
CONCLUSION
We fully agree with the considerations
made by Franco and Cedazo-Minguez, yet
it is our opinion that there are even other
important points to consider when mov-
ing with a drug from animals to humans.
Linked to this, we have brought forward
some critical issues related to the devel-
opment of cognition-enhancing drugs.
Indeed, many challenges are still open to
find an optimal strategy to translate animal
data into optimal clinical studies to eval-
uate the cognition-enhancing potential of
new drugs in humans.
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